Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real World Study of Mepolizumab in China
ChiCTR2500098669Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mepolizumab in eosinophilic asthma (EA), sponsored by Shanghai General Hospital. Primary endpoint: Change in rate of clinically significant exacerbations (CSE). Planned start Mar 2025; status: not yet recruiting.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on ChiCTR2500098669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098669.